Adducchio V S, Bibbolino C, Compagnucci M, Corpetti M G, Cortese A, Maddaloni E, Miele V, Scoppio M
V Divisione di Medicina Interna, Ospedale San Camillo, Roma.
Recenti Prog Med. 1997 Dec;88(12):585-7.
Antiphospholipid antibody syndrome (APS) is now recognized as one of the most important causes of hypercoagulability. The most common site for venous thrombosis in APS is deep venous thrombosis of the lower extremities. Other sites of venous thrombosis include retinal veins, renal veins, and hepatic veins. The authors report a case of splenic vein thrombosis disclosing antiphospholipid syndrome in which also the cytolytic effect of aPL may play a role of "cofactor" in the genesis of thrombosis through the release of thromboplastin from the lysis of red cells, granulocytes and platelets, making them vulnerable to clearance by splenic macrophages. Important considerations are stressed about differential diagnosis, etiopathogenetic factors, therapy and follow-up of the patient.
抗磷脂抗体综合征（APS）现已被公认为高凝状态最重要的病因之一。APS 中静脉血栓形成最常见的部位是下肢深静脉血栓形成。静脉血栓形成的其他部位包括视网膜静脉、肾静脉和肝静脉。作者报告了一例脾静脉血栓形成病例，该病例揭示了抗磷脂综合征，其中抗磷脂抗体（aPL）的细胞溶解作用可能通过红细胞、粒细胞和血小板溶解释放凝血活酶，在血栓形成过程中起到“辅助因子”的作用，使它们易于被脾巨噬细胞清除。文中强调了关于该患者鉴别诊断、病因发病因素、治疗及随访的重要注意事项。
